Moderna Advances Toward Broader Vaccine Portfolio with Key FDA Milestone

Moderna's mRNA-1010 flu vaccine is under FDA review, targeting a 2026/27 launch. This marks a key step in its post-COVID strategy, with stock up 66% YTD.

Moderna has achieved a critical regulatory milestone in its strategic pivot away from reliance on its COVID-19 vaccine. The U.S. Food and Drug Administration (FDA) has accepted for full review the company’s Biologics License Application for its influenza vaccine candidate, mRNA-1010. This move brings the potential commercial launch for the 2026/2027 flu season within reach, marking a significant step for the biotechnology firm's future.

Regulatory Hurdles Cleared After Strategic Shift

Securing this milestone followed a challenging path. The FDA had initially declined to review the application, citing concerns related to the proposed clinical trial design. Only after Moderna engaged in detailed discussions and revised its regulatory strategy did the agency agree to proceed with a comprehensive evaluation.

The company is now pursuing a standard approval pathway for adults aged 50 to 64. For individuals 65 and older, Moderna is seeking an accelerated approval, which would be contingent on a commitment to conduct a confirmatory post-marketing study. The success of this approach is viewed as a potential catalyst for reversing recent trends in product revenue.

A Pivotal Moment for Moderna's mRNA Platform

This development is strategically vital for Moderna as it seeks to demonstrate the broader application of its mRNA technology beyond the pandemic. The candidate is under regulatory review not only in the United States but also in Europe, Canada, and Australia. Company leadership is pinning considerable hopes on its respiratory disease portfolio to help move past the net losses reported last year.

Financial projections for 2026 anticipate sales growth of up to 10%, driven largely by the international commercialization of new vaccine products. The market responded favorably to the news. Moderna's stock, closing at €43.83 on Thursday, has surged more than 66% since the start of the year and now trades just fractionally below its current 52-week high.

Summer 2026 Set as Decision Deadline

The FDA has set a target date of August 5, 2026, for its final decision on mRNA-1010. Should approval be granted, Moderna plans to make the vaccine available immediately for the subsequent winter season. In the interim, investor focus will likely remain fixed on further progress in international regulatory processes and the execution of the company's 2026 growth objectives.

• Latest Close (Thursday): €43.83
• Year-to-Date Performance: +66.37%
• 52-Week High: €44.15 (January 22, 2026)